Leap Therapeutics IncNASDAQ:LPTX
- LAST PRICE2.7200
- TODAY'S CHANGE (%)0.0800 (3.0303%)
- Bid / Lots2.5000/ 2
- Ask / Lots2.9600/ 1
- Open / Previous Close2.6800 / 2.6400
- Day Range
- 52 Week Range
- Volume188,154
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LPTX |
|---|---|---|
| 09:32 ET | 2789 | 2.69 |
| 09:33 ET | 712 | 2.5655 |
| 09:35 ET | 100 | 2.6181 |
| 09:37 ET | 701 | 2.5623 |
| 09:42 ET | 1100 | 2.616 |
| 09:44 ET | 5000 | 2.556 |
| 09:46 ET | 14393 | 2.7 |
| 09:48 ET | 300 | 2.6 |
| 09:50 ET | 369 | 2.6 |
| 09:53 ET | 250 | 2.5613 |
| 09:55 ET | 648 | 2.625 |
| 10:06 ET | 200 | 2.61 |
| 10:13 ET | 100 | 2.64 |
| 10:15 ET | 100 | 2.64 |
| 10:22 ET | 624 | 2.635 |
| 10:26 ET | 100 | 2.6343 |
| 10:36 ET | 200 | 2.65 |
| 10:40 ET | 1000 | 2.635 |
| 10:47 ET | 1200 | 2.64 |
| 10:49 ET | 100 | 2.64 |
| 11:03 ET | 200 | 2.63 |
| 11:05 ET | 200 | 2.63 |
| 11:07 ET | 100 | 2.62 |
| 11:09 ET | 100 | 2.62 |
| 11:16 ET | 100 | 2.64 |
| 11:18 ET | 2700 | 2.64 |
| 11:20 ET | 600 | 2.62 |
| 11:25 ET | 100 | 2.6385 |
| 11:27 ET | 917 | 2.62 |
| 11:30 ET | 11710 | 2.61 |
| 11:32 ET | 500 | 2.6 |
| 11:34 ET | 500 | 2.5801 |
| 11:39 ET | 650 | 2.62 |
| 11:43 ET | 100 | 2.62 |
| 11:48 ET | 7006 | 2.66 |
| 11:50 ET | 700 | 2.7 |
| 11:54 ET | 9868 | 2.69 |
| 11:57 ET | 1210 | 2.67 |
| 11:59 ET | 2100 | 2.685 |
| 12:01 ET | 150 | 2.6969 |
| 12:03 ET | 100 | 2.69 |
| 12:10 ET | 6400 | 2.72 |
| 12:12 ET | 3985 | 2.73 |
| 12:14 ET | 1400 | 2.7199 |
| 12:21 ET | 1997 | 2.71 |
| 12:26 ET | 200 | 2.725 |
| 12:30 ET | 100 | 2.725 |
| 12:32 ET | 1960 | 2.755 |
| 12:33 ET | 979 | 2.755 |
| 12:35 ET | 300 | 2.7201 |
| 12:39 ET | 2300 | 2.755 |
| 12:42 ET | 3400 | 2.755 |
| 12:46 ET | 220 | 2.775 |
| 12:48 ET | 500 | 2.78 |
| 12:50 ET | 432 | 2.7949 |
| 12:53 ET | 2260 | 2.79 |
| 01:02 ET | 1100 | 2.79 |
| 01:04 ET | 6369 | 2.82 |
| 01:08 ET | 1800 | 2.82 |
| 01:22 ET | 1623 | 2.83 |
| 01:26 ET | 5199 | 2.815 |
| 01:27 ET | 3120 | 2.81 |
| 01:31 ET | 250 | 2.8001 |
| 01:33 ET | 2609 | 2.805 |
| 01:38 ET | 5195 | 2.77 |
| 01:40 ET | 100 | 2.775 |
| 02:00 ET | 2399 | 2.7899 |
| 02:02 ET | 300 | 2.78 |
| 02:03 ET | 200 | 2.78 |
| 02:05 ET | 834 | 2.78 |
| 02:09 ET | 1600 | 2.76 |
| 02:12 ET | 200 | 2.76 |
| 02:14 ET | 100 | 2.76 |
| 02:20 ET | 2650 | 2.765 |
| 02:21 ET | 185 | 2.7532 |
| 02:23 ET | 380 | 2.755 |
| 02:25 ET | 210 | 2.74 |
| 02:32 ET | 2620 | 2.7101 |
| 02:45 ET | 1550 | 2.695 |
| 02:48 ET | 900 | 2.695 |
| 02:50 ET | 800 | 2.69 |
| 02:52 ET | 200 | 2.7 |
| 02:54 ET | 400 | 2.74 |
| 02:56 ET | 100 | 2.715 |
| 02:57 ET | 5809 | 2.7 |
| 02:59 ET | 500 | 2.69 |
| 03:01 ET | 554 | 2.69 |
| 03:03 ET | 1000 | 2.69 |
| 03:06 ET | 8200 | 2.72 |
| 03:10 ET | 100 | 2.7426 |
| 03:14 ET | 5890 | 2.7 |
| 03:17 ET | 200 | 2.6994 |
| 03:24 ET | 100 | 2.69 |
| 03:26 ET | 200 | 2.695 |
| 03:28 ET | 245 | 2.68 |
| 03:30 ET | 1000 | 2.6874 |
| 03:35 ET | 100 | 2.69 |
| 03:44 ET | 100 | 2.695 |
| 03:46 ET | 100 | 2.71 |
| 03:48 ET | 1739 | 2.71 |
| 03:50 ET | 220 | 2.71 |
| 03:51 ET | 731 | 2.71 |
| 03:53 ET | 2476 | 2.7 |
| 03:55 ET | 200 | 2.6823 |
| 03:57 ET | 301 | 2.7 |
| 04:00 ET | 3362 | 2.72 |
Nov 21, 2023
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference, from 7:00AM ET on Tuesday Nov 21, 2023 by Dow Jones
7:00AM ET on Tuesday Nov 21, 2023 by Dow Jones
Nov 20, 2023
DJ Leap Therapeutics Is Maintained at Buy by Mizuho, from 10:50AM ET on Monday Nov 20, 2023 by Dow Jones
10:50AM ET on Monday Nov 20, 2023 by Dow Jones
Nov 14, 2023
DJ Leap Therapeutics Is Maintained at Outperform by Raymond James, from 3:52AM ET on Tuesday Nov 14, 2023 by Dow Jones
3:52AM ET on Tuesday Nov 14, 2023 by Dow Jones
Nov 13, 2023
Leap Therapeutics Reports Third Quarter 2023 Financial Results, from 7:00AM ET on Monday Nov 13, 2023 by Dow Jones
7:00AM ET on Monday Nov 13, 2023 by Dow Jones*DJ Leap Therapeutics 3Q Loss/Shr 51c >LPTX, from 7:00AM ET on Monday Nov 13, 2023 by Dow Jones
7:00AM ET on Monday Nov 13, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Leap Therapeutics Inc | 67.5M | -0.5x | --- |
NKGen Biotech Inc | 66.5M | -0.9x | --- |
Checkpoint Therapeutics Inc | 68.0M | -0.6x | --- |
Kronos Bio Inc | 68.8M | -0.6x | --- |
BioVie Inc | 65.7M | -1.2x | --- |
Bioatla Inc | 65.7M | -0.5x | --- |
Company Information
Leap Therapeutics, Inc. is a biotechnology company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company’s pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. It also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
Contact Information
- Headquarters
- 47 Thorndike St Ste B1-1CAMBRIDGE, MA, United States 02141-1799
- Phone
- 617-252-4343
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Christopher Mirabelli
- President, Chief Executive Officer, Director
- Douglas Onsi
- Chief Operating Officer
- Augustine Lawlor
- Chief Scientific Officer
- Jason Baum
- Vice President, Head - Regulatory Affairs and Quality
- Christine Granfield
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $67.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-5.72 |
Book Value | $5.94 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
